Soleus Capital Management, L.P. 13F annual report
Soleus Capital Management, L.P. is an investment fund managing more than $1.13 trillion ran by Harold Schaaff. There are currently 92 companies in Mr. Schaaff’s portfolio. The largest investments include TG Therapeutics Inc and Iovance Biotherapeutics Inc, together worth $125 billion.
$1.13 trillion Assets Under Management (AUM)
As of 7th August 2024, Soleus Capital Management, L.P.’s top holding is 3,645,562 shares of TG Therapeutics Inc currently worth over $64.9 billion and making up 5.7% of the portfolio value.
Relative to the number of outstanding shares of TG Therapeutics Inc, Soleus Capital Management, L.P. owns more than approximately 0.1% of the company.
In addition, the fund holds 7,548,000 shares of Iovance Biotherapeutics Inc worth $60.5 billion, whose value grew 12.5% in the past six months.
The third-largest holding is United Therapeutics Corp worth $45.1 billion and the next is Nurix Therapeutics worth $42.9 billion, with 2,055,916 shares owned.
Currently, Soleus Capital Management, L.P.'s portfolio is worth at least $1.13 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Soleus Capital Management, L.P.
The Soleus Capital Management, L.P. office and employees reside in Greenwich, Connecticut. According to the last 13-F report filed with the SEC, Harold Schaaff serves as the Chief Compliance Officer, Soleus Capital Management, L.P. at Soleus Capital Management, L.P..
Recent trades
In the most recent 13F filing, Soleus Capital Management, L.P. revealed that it had opened a new position in
Terns Pharmaceuticals Inc and bought 4,947,738 shares worth $33.7 billion.
The investment fund also strengthened its position in TG Therapeutics Inc by buying
477,106 additional shares.
This makes their stake in TG Therapeutics Inc total 3,645,562 shares worth $64.9 billion.
TG Therapeutics Inc soared 91.3% in the past year.
On the other hand, there are companies that Soleus Capital Management, L.P. is getting rid of from its portfolio.
Soleus Capital Management, L.P. closed its position in HCA Healthcare Inc on 14th August 2024.
It sold the previously owned 51,441 shares for $17.2 billion.
Harold Schaaff also disclosed a decreased stake in United Therapeutics Corp by 0.5%.
This leaves the value of the investment at $45.1 billion and 141,499 shares.
One of the average hedge funds
The two most similar investment funds to Soleus Capital Management, L.P. are Private Ocean and Ascent. They manage $1.13 trillion and $1.13 trillion respectively.
Harold Schaaff investment strategy
Soleus Capital Management, L.P.’s portfolio is diversified across 4 sectors.
Currently, their heaviest sector is Health Care — making up 74.3% of
the total portfolio value.
The fund focuses on investments in the United States as
53.3% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
11% of the total holdings value.
On the other hand, large-cap stocks make up only 7.6% of the portfolio.
The average market cap of the portfolio companies is close to $6.83 billion.
The complete list of Soleus Capital Management, L.P. trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| TG Therapeutics Inc |
15.06%
3,645,562
|
$64,854,548,000 | 5.72% |
| Iovance Biotherapeutics Inc |
115.35%
7,548,000
|
$60,534,960,000 | 5.34% |
| United Therapeutics Corp |
45.52%
141,499
|
$45,074,506,000 | 3.97% |
| Nurix Therapeutics, Inc. |
84.39%
2,055,916
|
$42,906,967,000 | 3.78% |
| EDAP TMS S.A. |
0.92%
7,293,728
|
$39,677,880,000 | 3.50% |
| Terns Pharmaceuticals Inc |
Opened
4,947,738
|
$33,694,096,000 | 2.97% |
| Revolution Medicines Inc |
17.49%
856,178
|
$33,228,268,000 | 2.93% |
| Surmodics, Inc. |
2.38%
781,777
|
$32,865,905,000 | 2.90% |
| Organogenesis Holdings Inc. |
20.33%
11,518,954
|
$32,253,071,000 | 2.84% |
| Jasper Therapeutics Inc |
7.51%
1,276,190
|
$28,969,513,000 | 2.55% |
| IDEAYA Biosciences, Inc. |
30.09%
694,069
|
$24,368,763,000 | 2.15% |
| Axogen Inc. |
6.44%
3,305,815
|
$23,934,101,000 | 2.11% |
| Krystal Biotech Inc |
49.82%
126,000
|
$23,138,640,000 | 2.04% |
| Merus N.V |
92.42%
376,321
|
$22,266,914,000 | 1.96% |
| Penumbra Inc |
44.05%
123,450
|
$22,217,297,000 | 1.96% |
| Essa Pharma Inc |
17.30%
4,210,537
|
$22,147,425,000 | 1.95% |
| Praxis Precision Medicines I |
1,330.22%
533,015
|
$22,045,500,000 | 1.94% |
| Celcuity Inc |
30.04%
1,211,187
|
$19,839,243,000 | 1.75% |
| Inari Med Inc |
47.43%
408,373
|
$19,663,160,000 | 1.73% |
| BeiGene Ltd |
7.02%
137,700
|
$19,645,659,000 | 1.73% |
| C4 Therapeutics, Inc. |
64.78%
4,051,996
|
$18,720,222,000 | 1.65% |
| Castle Biosciences, Inc. |
17.67%
853,628
|
$18,583,482,000 | 1.64% |
| Neuropace Inc |
No change
2,433,168
|
$18,394,750,000 | 1.62% |
| Enliven Therapeutics Inc |
Opened
769,263
|
$17,977,676,000 | 1.59% |
| Alnylam Pharmaceuticals Inc |
Opened
71,700
|
$17,423,100,000 | 1.54% |
| HCA Healthcare Inc |
Closed
51,441
|
$17,157,117,000 | |
| Syndax Pharmaceuticals Inc |
123.98%
826,500
|
$16,968,045,000 | 1.50% |
| Humana Inc. |
38.40%
44,356
|
$16,573,619,000 | 1.46% |
| GSK Plc |
30.01%
415,000
|
$15,977,500,000 | 1.41% |
| Treace Med Concepts Inc |
75.80%
2,365,648
|
$15,731,559,000 | 1.39% |
| Biogen Inc |
Closed
72,800
|
$15,697,864,000 | |
| Vaxcyte, Inc. |
10.83%
185,250
|
$13,988,228,000 | 1.23% |
| 10x Genomics, Inc. |
Opened
719,000
|
$13,984,550,000 | 1.23% |
| Rigel Pharmaceuticals |
Closed
9,241,986
|
$13,678,139,000 | |
| Cg Oncology Inc |
94.88%
424,585
|
$13,404,148,000 | 1.18% |
| Nuvalent Inc |
32.87%
171,788
|
$13,031,838,000 | 1.15% |
| Evolus Inc |
620.00%
1,152,000
|
$12,499,200,000 | 1.10% |
| Enanta Pharmaceuticals Inc |
37.72%
799,546
|
$10,370,112,000 | 0.91% |
| Alector, Inc. |
Opened
2,239,006
|
$10,165,087,000 | 0.90% |
| Keros Therapeutics, Inc. |
19.01%
221,600
|
$10,127,120,000 | 0.89% |
| Teva Pharmaceutical Inds Ltd |
83.18%
586,499
|
$9,530,609,000 | 0.84% |
| Arcellx Inc |
13.83%
170,741
|
$9,423,196,000 | 0.83% |
| Inhibrx, Inc. |
Closed
267,871
|
$9,364,770,000 | |
| Biodesix Inc |
Opened
6,111,964
|
$9,351,305,000 | 0.82% |
| Tango Therapeutics Inc |
22.24%
1,049,895
|
$9,008,099,000 | 0.79% |
| OrthoPediatrics corp |
Opened
309,500
|
$8,901,220,000 | 0.78% |
| Rigel Pharmaceuticals |
Opened
1,043,697
|
$8,579,189,000 | 0.76% |
| Bausch Health Cos Inc |
80.00%
1,206,000
|
$8,405,820,000 | 0.74% |
| Immunic, Inc. |
No change
7,293,007
|
$8,095,238,000 | 0.71% |
| Y-Mabs Therapeutics Inc |
13.49%
647,982
|
$7,827,623,000 | 0.69% |
| Engene Holdings Inc |
No change
800,000
|
$7,544,000,000 | 0.67% |
| Pharvaris N V |
0.61%
399,430
|
$7,509,284,000 | 0.66% |
| Avadel Pharmaceuticals plc |
Opened
509,000
|
$7,156,540,000 | 0.63% |
| Dyne Therapeutics, Inc. |
Opened
201,000
|
$7,093,290,000 | 0.63% |
| Mannkind Corp |
Closed
1,558,537
|
$7,060,173,000 | |
| Mind Medicine Mindmed Inc |
Closed
750,237
|
$7,052,228,000 | |
| Cvrx Inc |
1,110.51%
587,098
|
$7,039,305,000 | 0.62% |
| Insmed Inc |
59.01%
102,472
|
$6,865,624,000 | 0.61% |
| Hims & Hers Health, Inc. |
Opened
333,000
|
$6,723,270,000 | 0.59% |
| Theratechnologies Inc. |
No change
4,801,376
|
$6,721,926,000 | 0.59% |
| Immunovant Inc |
4.82%
251,900
|
$6,650,160,000 | 0.59% |
| Adaptive Biotechnologies Cor |
Opened
1,720,000
|
$6,226,400,000 | 0.55% |
| Applied Therapeutics, Inc. |
18.86%
1,269,714
|
$5,929,564,000 | 0.52% |
| Globus Med Inc |
Opened
86,000
|
$5,890,140,000 | 0.52% |
| Jazz Pharmaceuticals plc |
Opened
53,935
|
$5,756,483,000 | 0.51% |
| Viking Therapeutics Inc |
Closed
67,121
|
$5,503,922,000 | |
| BioAtla, Inc. |
4.03%
3,901,314
|
$5,344,800,000 | 0.47% |
| Erasca Inc |
Opened
2,162,162
|
$5,102,702,000 | 0.45% |
| Verastem Inc |
7.83%
1,661,297
|
$4,950,665,000 | 0.44% |
| COMPASS Pathways plc |
Closed
565,550
|
$4,705,376,000 | |
| KalVista Pharmaceuticals Inc |
Closed
386,000
|
$4,577,960,000 | |
| Regulus Therapeutics Inc |
Closed
1,562,500
|
$4,500,000,000 | |
| Mereo BioPharma Group plc |
52.35%
1,246,953
|
$4,489,031,000 | 0.40% |
| Iradimed Corp |
71.78%
102,067
|
$4,484,824,000 | 0.40% |
| Viridian Therapeutics Inc |
No change
340,000
|
$4,423,400,000 | 0.39% |
| Exact Sciences Corp. |
Opened
91,611
|
$3,870,565,000 | 0.34% |
| Insulet Corporation |
Opened
18,800
|
$3,793,840,000 | 0.33% |
| Kiniksa Pharmaceuticals Intl |
Opened
200,000
|
$3,734,000,000 | 0.33% |
| InspireMD Inc |
No change
1,378,128
|
$3,438,843,000 | 0.30% |
| Nkarta, Inc. |
Closed
300,000
|
$3,243,000,000 | |
| Calcimedica Inc |
No change
783,904
|
$3,104,260,000 | 0.27% |
| The Beauty Health Company |
843.95%
1,604,718
|
$3,081,059,000 | 0.27% |
| Sanofi |
Opened
62,500
|
$3,032,500,000 | 0.27% |
| Dianthus Therapeutics Inc |
Closed
100,000
|
$3,000,000,000 | |
| Fate Therapeutics Inc |
No change
870,000
|
$2,853,600,000 | 0.25% |
| Taysha Gene Therapies, Inc. |
Closed
925,000
|
$2,654,750,000 | |
| X4 Pharmaceuticals, Inc. |
11.55%
4,051,000
|
$2,349,580,000 | 0.21% |
| Olema Pharmaceuticals, Inc. |
67.10%
216,500
|
$2,342,530,000 | 0.21% |
| Janux Therapeutics Inc |
64.83%
55,500
|
$2,324,895,000 | 0.21% |
| 4d Molecular Therapeutics In |
44.90%
108,598
|
$2,279,472,000 | 0.20% |
| Genedx Holdings Corp |
88.89%
87,000
|
$2,274,180,000 | 0.20% |
| Arcutis Biotherapeutics Inc |
Closed
225,000
|
$2,229,750,000 | |
| Cervomed Inc |
No change
126,614
|
$2,167,632,000 | 0.19% |
| AVITA Medical Inc |
256.00%
267,000
|
$2,114,640,000 | 0.19% |
| Annexon Inc |
Closed
292,400
|
$2,096,508,000 | |
| NovoCure Ltd |
84.35%
108,900
|
$1,865,457,000 | 0.16% |
| Apogee Therapeutics Inc |
Closed
20,000
|
$1,329,000,000 | |
| Inhibrx Biosciences Inc |
Opened
88,470
|
$1,253,620,000 | 0.11% |
| TransMedics Group, Inc. |
Closed
16,700
|
$1,234,798,000 | |
| Oric Pharmaceuticals, Inc. |
61.28%
163,000
|
$1,152,410,000 | 0.10% |
| Adverum Biotechnologies Inc |
Opened
147,246
|
$1,010,108,000 | 0.09% |
| Protagonist Therapeutics Inc |
Closed
34,500
|
$998,085,000 | |
| Denali Therapeutics Inc |
Closed
47,000
|
$964,440,000 | |
| Amicus Therapeutics Inc |
Closed
57,966
|
$682,839,000 | |
| Establishment Labs Holdings Inc |
Opened
15,000
|
$681,600,000 | 0.06% |
| Orthofix Med Inc |
Opened
51,000
|
$676,260,000 | 0.06% |
| Tenaya Therapeutics Inc |
Closed
122,222
|
$639,221,000 | |
| MiMedx Group, Inc |
Opened
82,884
|
$574,386,000 | 0.05% |
| Aadi Bioscience Inc |
Opened
333,227
|
$486,511,000 | 0.04% |
| Bicycle Therapeutics plc |
84.64%
23,500
|
$475,640,000 | 0.04% |
| Natera Inc |
95.86%
3,600
|
$389,844,000 | 0.03% |
| Io Biotech Inc |
Opened
192,670
|
$225,424,000 | 0.02% |
| Silk Rd Med Inc |
Closed
10,000
|
$183,200,000 | |
| UroGen Pharma Ltd |
Closed
10,000
|
$150,000,000 | |
| Liquidia Corp |
Closed
10,000
|
$147,500,000 | |
| Xeris Biopharma Holdings Inc |
No change
62,083
|
$139,687,000 | 0.01% |
| No transactions found | |||
| Showing first 500 out of 116 holdings | |||
Hedge funds similar to Soleus Capital Management, L.P.
- Waterfront Capital Partners
- Clear Harbor Asset Management
- Francisco Partners Management, L.P.
- Mesirow Institutional Investment Management
- Jaffetilchin Investment Partners
- Simplify Asset Management
- Ascent
- Private Ocean
- Trinity Street Asset Management LL.P.
- Cahaba Wealth Management, Inc
- Dnca Finance
- Gladstone Capital Management LL.P.
- E-l Corp Ltd
- Wolverine Asset Management